Anthony M. Insogna

Career

Anthony M. Insogna leads Jones Day’s IP Practice of over 200 professionals worldwide handling complex IP litigation, patent, trademark and copyright strategies, and licensing for the world’s leading innovators and brands. Anthony has more than 30 years of experience handling high-stakes patent litigation, global patent strategies, and collaborations and licensing for life sciences companies. A trusted advisor for innovators on Hatch-Waxman and PTAB litigation, he is also steeped in cutting-edge technologies, including antibody and conjugates, immuno-oncology, CRISPR-Cas9 (gene editing), gene therapies, and vaccines.

Anthony’s recent Hatch-Waxman representations include Bristol Myers Squibb’s REVLIMID®, one of the world's top-selling drugs, and POMALYST® matters, and BRIDION® for Merck & Co. Helming teams in 83 IPRs challenges directed at life sciences patent owners to date, Anthony has achieved an institution denial rate for patentees of 70%—28% above the average life-sciences denial rate, and for petitioners, a track rate at institution well above the life sciences institution rate.

Anthony is also representing ToolGen in two patent interferences involving CRISPR/Cas9 technology. In the biopharmaceutical sector, seeking treatments for cancer, Anthony is currently developing worldwide patent portfolio strategies for several companies with late-stage clinical candidates.